-
Something wrong with this record ?
Spectroscopic abnormalities in the pregenual anterior cingulate cortex in obsessive-compulsive disorder using proton magnetic resonance spectroscopy: a controlled study
E. Kosová, D. Pajuelo, I. Fajnerová, D. Greguš, M. Brunovský, P. Stopková, A. Škoch, P. Fürstová, F. Španiel, J. Horáček
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
BioMedCentral
from 2001-01-12
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-06-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
Psychology Database (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Gyrus Cinguli diagnostic imaging metabolism MeSH
- Glutamine * metabolism MeSH
- Inositol metabolism therapeutic use MeSH
- Creatine metabolism therapeutic use MeSH
- Aspartic Acid metabolism therapeutic use MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Obsessive-Compulsive Disorder * diagnosis MeSH
- Proton Magnetic Resonance Spectroscopy methods MeSH
- Receptors, Antigen, T-Cell metabolism therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: The main aim of the present study is to determine the role of metabolites observed using proton magnetic resonance spectroscopy (1H-MRS) in obsessive-compulsive disorder (OCD). As the literature describing biochemical changes in OCD yields conflicting results, we focused on accurate metabolite quantification of total N-acetyl aspartate (tNAA), total creatine (tCr), total choline-containing compounds (tCh), and myo-inositol (mI) in the anterior cingulate cortex (ACC) to capture the small metabolic changes between OCD patients and controls and between OCD patients with and without medication. METHODS: In total 46 patients with OCD and 46 healthy controls (HC) matched for age and sex were included in the study. The severity of symptoms in the OCD was evaluated on the day of magnetic resonance imaging (MRI) using the Yale-Brown Obsessive-Compulsive Scale (YBOCS). Subjects underwent 1H-MRS from the pregenual ACC (pgACC) region to calculate concentrations of tNAA, tCr, tCho, and mI. Twenty-eight OCD and 28 HC subjects were included in the statistical analysis. We compared differences between groups for all selected metabolites and in OCD patients we analyzed the relationship between metabolite levels and symptom severity, medication status, age, and the duration of illness. RESULTS: Significant decreases in tCr (U = 253.00, p = 0.022) and mI (U = 197.00, p = 0.001) in the pgACC were observed in the OCD group. No statistically significant differences were found in tNAA and tCho levels; however, tCho revealed a trend towards lower concentrations in OCD patients (U = 278.00, p = 0.062). Metabolic concentrations showed no significant correlations with the age and duration of illness. The correlation statistics found a significant negative correlation between tCr levels and YBOCS compulsions subscale (cor = -0.380, p = 0.046). tCho and YBOCS compulsions subscale showed a trend towards a negative correlation (cor = -0.351, p = 0.067). Analysis of subgroups with or without medication showed no differences. CONCLUSIONS: Patients with OCD present metabolic disruption in the pgACC. The decrease in tCr shows an important relationship with OCD symptomatology. tCr as a marker of cerebral bioenergetics may also be considered as a biomarker of the severity of compulsions. The study failed to prove that metabolic changes correlate with the medication status or the duration of illness. It seems that a disruption in the balance between these metabolites and their transmission may play a role in the pathophysiology of OCD.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001065
- 003
- CZ-PrNML
- 005
- 20240213093606.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12888-023-05228-3 $2 doi
- 035 __
- $a (PubMed)37817131
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kosová, Eliška $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Spectroscopic abnormalities in the pregenual anterior cingulate cortex in obsessive-compulsive disorder using proton magnetic resonance spectroscopy: a controlled study / $c E. Kosová, D. Pajuelo, I. Fajnerová, D. Greguš, M. Brunovský, P. Stopková, A. Škoch, P. Fürstová, F. Španiel, J. Horáček
- 520 9_
- $a BACKGROUND: The main aim of the present study is to determine the role of metabolites observed using proton magnetic resonance spectroscopy (1H-MRS) in obsessive-compulsive disorder (OCD). As the literature describing biochemical changes in OCD yields conflicting results, we focused on accurate metabolite quantification of total N-acetyl aspartate (tNAA), total creatine (tCr), total choline-containing compounds (tCh), and myo-inositol (mI) in the anterior cingulate cortex (ACC) to capture the small metabolic changes between OCD patients and controls and between OCD patients with and without medication. METHODS: In total 46 patients with OCD and 46 healthy controls (HC) matched for age and sex were included in the study. The severity of symptoms in the OCD was evaluated on the day of magnetic resonance imaging (MRI) using the Yale-Brown Obsessive-Compulsive Scale (YBOCS). Subjects underwent 1H-MRS from the pregenual ACC (pgACC) region to calculate concentrations of tNAA, tCr, tCho, and mI. Twenty-eight OCD and 28 HC subjects were included in the statistical analysis. We compared differences between groups for all selected metabolites and in OCD patients we analyzed the relationship between metabolite levels and symptom severity, medication status, age, and the duration of illness. RESULTS: Significant decreases in tCr (U = 253.00, p = 0.022) and mI (U = 197.00, p = 0.001) in the pgACC were observed in the OCD group. No statistically significant differences were found in tNAA and tCho levels; however, tCho revealed a trend towards lower concentrations in OCD patients (U = 278.00, p = 0.062). Metabolic concentrations showed no significant correlations with the age and duration of illness. The correlation statistics found a significant negative correlation between tCr levels and YBOCS compulsions subscale (cor = -0.380, p = 0.046). tCho and YBOCS compulsions subscale showed a trend towards a negative correlation (cor = -0.351, p = 0.067). Analysis of subgroups with or without medication showed no differences. CONCLUSIONS: Patients with OCD present metabolic disruption in the pgACC. The decrease in tCr shows an important relationship with OCD symptomatology. tCr as a marker of cerebral bioenergetics may also be considered as a biomarker of the severity of compulsions. The study failed to prove that metabolic changes correlate with the medication status or the duration of illness. It seems that a disruption in the balance between these metabolites and their transmission may play a role in the pathophysiology of OCD.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a protonová magnetická rezonanční spektroskopie $x metody $7 D066244
- 650 12
- $a glutamin $x metabolismus $7 D005973
- 650 _2
- $a cingulární gyrus $x diagnostické zobrazování $x metabolismus $7 D006179
- 650 12
- $a obsedantně kompulzivní porucha $x diagnóza $7 D009771
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a inositol $x metabolismus $x terapeutické užití $7 D007294
- 650 _2
- $a kyselina asparagová $x metabolismus $x terapeutické užití $7 D001224
- 650 _2
- $a kreatin $x metabolismus $x terapeutické užití $7 D003401
- 650 _2
- $a receptory antigenů T-buněk $x metabolismus $x terapeutické užití $7 D011948
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pajuelo, Dita $u Third Faculty of Medicine, Charles University, Prague, Czech Republic. diwa@ikem.cz $u MR Unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. diwa@ikem.cz
- 700 1_
- $a Fajnerová, Iveta $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Greguš, David $u National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Brunovský, Martin $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Stopková, Pavla $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Škoch, Antonín $u National Institute of Mental Health, Klecany, Czech Republic $u MR Unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Fürstová, Petra $u National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Španiel, Filip $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Horáček, Jiří $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00008204 $t BMC psychiatry $x 1471-244X $g Roč. 23, č. 1 (2023), s. 734
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37817131 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093603 $b ABA008
- 999 __
- $a ok $b bmc $g 2049587 $s 1210759
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 1 $d 734 $e 20231010 $i 1471-244X $m BMC psychiatry $n BMC Psychiatry $x MED00008204
- LZP __
- $a Pubmed-20240109